Stock Events

Stock Events

Seres Therapeutics 

€7.4
0
+€0.2+2.78% Wednesday 19:47

Statistics

Day High
7.4
Day Low
7.4
52W High
24.4
52W Low
6.43
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q4 2025
Next
-1.83
-1.74
-1.64
-1.55
Expected EPS
-1.592172
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1S90.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Synlogic
SYBX
Mkt Cap7.31M
Synlogic operates in the synthetic biotic medicines space, directly competing with Seres Therapeutics in developing treatments for diseases using microbiome engineering.
Regenxbio
RGNX
Mkt Cap454.19M
REGENXBIO is involved in gene therapy, which overlaps with Seres's work on microbiome therapeutics, especially in targeting similar diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals, with its focus on creating transformative medicines, competes in the cystic fibrosis market where Seres also aims to make an impact through microbiome therapies.
NervGen Pharma
NGENF
Mkt Cap445.97M
4D Pharma researches and develops live biotherapeutic products, a direct competition to Seres's microbiome therapeutic products.
Evelo Biosciences
EVLO
Mkt Cap1,898
Evelo Biosciences focuses on developing microbiome therapeutics, making it a direct competitor in Seres's core market.
Seres Therapeutics
MCRB
Mkt Cap79.76M
Seres Therapeutics is listed as its own competitor due to an error. Please disregard.
Axsome Therapeutics
AXSM
Mkt Cap9.11B
Axsome Therapeutics, while primarily focused on CNS disorders, represents potential competition in the broader biotech space for innovative treatments, including microbiome therapies.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics, with its gene-editing technology, competes in the innovative treatment space, including potential overlaps in disease areas targeted by Seres.

About

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Richard N. Kender B.S., M.B.A.
Employees
66
Country
United States
ISIN
US81750R2013

Listings

F
DE
1S90.F
MU
DE
1S90.MU
STU
DE
1S90.STU
XNAS
US
MCRB

0 Comments

Share your thoughts

FAQ

What is Seres Therapeutics stock price today?▼
The current price of 1S90.STU is €7.4 EUR — it has increased by +2.78% in the past 24 hours. Watch Seres Therapeutics stock price performance more closely on the chart.
What is Seres Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Seres Therapeutics stocks are traded under the ticker 1S90.STU.
Is Seres Therapeutics stock price growing?▼
1S90.STU stock has risen by +0.95% compared to the previous week, the month change is a +0.41% rise, over the last year Seres Therapeutics has showed a +10.05% increase.
When is the next Seres Therapeutics earnings date?▼
Seres Therapeutics is going to release the next earnings report on May 13, 2026.
What were Seres Therapeutics earnings last quarter?▼
1S90.STU earnings for the last quarter are -1.55 EUR per share, whereas the estimation was -1.83 EUR resulting in a +15.64% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Seres Therapeutics have?▼
As of April 16, 2026, the company has 66 employees.
In which sector is Seres Therapeutics located?▼
Seres Therapeutics operates in the Other sector.
When did Seres Therapeutics complete a stock split?▼
Seres Therapeutics has not had any recent stock splits.
Where is Seres Therapeutics headquartered?▼
Seres Therapeutics is headquartered in Cambridge, United States.